It was developed by PDL (Incline Village, NV, USA) and subsequently licensed to Biogen-Idec, Ophthotech (New York, NY, USA) and…
The overall survival rate was 20.2 months for patients with PD-L1 high-expressing tumors treated with atezolizumab compared to 13.1 months…